SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Arlin, Z. A. Articles by Fuhr, H. G. Search for Related Content PubMed PubMed Citation Articles by Arlin, Z. A. Articles by Fuhr, H. G. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults ZA Arlin, E Feldman, S Kempin, T Ahmed, A Mittelman, S Savona, J Ascensao, P Baskind, P Sullivan and HG Fuhr Department of Medicine, New York Medical College, Valhalla 10595. Thirty-six patients with relapsed acute lymphoblastic leukemia (ALL) and four with primary refractory ALL were treated with a regimen that included amsacrine, 200 mg/m2, intravenously daily for three days with cytarabine, 3 gm/m2, by infusion over three hours daily for five days. There were 27 remissions in the 36 relapsed patients and two in the four patients with primary refractory disease. Seventeen of the 23 patients with common ALL, four of the six with T-cell ALL, one of the three with B-cell ALL, and seven of eight whose cells were not characterized responded. Toxicity of this regimen was comparable to other reinduction regimens for ALL, but the side effects characteristic of high-dose cytarabine therapy were absent. Since these results compare favorably with conventional induction regimens, its use in the primary treatment of adults and children with high-risk ALL is proposed. Volume 72, Issue 2, pp. 433-435, 08/01/1988 Copyright © 1988 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: W. J. Sung, D. H. Kim, S. K. Sohn, J. G. Kim, J. H. Baek, S. B. Jeon, J. H. Moon, B. M. Ahn, and K. B. Lee Phase II Trial of Amsacrine Plus Intermediate-dose Ara-C (IDAC) with or without Etoposide as Salvage Therapy for Refractory or Relapsed Acute Leukemia Jpn. J. Clin. Oncol., October 1, 2005; 35(10): 612 - 616. [Abstract] [Full Text] [PDF]

	Copyright © 1988 by American Society of Hematology         Online ISSN: 1528-0020